Targeting AURKA activation using inhibitors like MLN8237 (Alisertib) in pancreatic cancers (PancT4 cell line and Primary cells from tumors) suppresses tumor formation (Neel et al., 2014). This evidence concerns the gene AURKA and neoplasm.